ELOQUENT-2 Study in Patients With Relapsed/Refractory Multiple Myeloma
Sagar Lonial, MD, professor, School of Medicine, executive vice chair, Department of Hematology & Medical Oncology, chief medical officer, Winship Cancer Institute, Emory University, discusses the ELOQUENT-2 study in patients with relapsed/refractory multiple myeloma.
The trial was based on results from early phase I/II trials that showed that elotuzumab and lenalidomide are synergistic when given together, said Lonial. There was also a better overall response rate and longer progression-free survival with the addition of elotuzumab.
Lonial says more than 300 patients were randomized to each arm, and roughly one-third of patients had high-risk disease at the time of initial presentation.
Sagar Lonial, MD, professor, School of Medicine, executive vice chair, Department of Hematology & Medical Oncology, chief medical officer, Winship Cancer Institute, Emory University, discusses the ELOQUENT-2 study in patients with relapsed/refractory multiple myeloma. This was a randomized phase III trial that evaluated the benefit of elotuzumab in combination with lenalidomide and dexamethasone versus lenalidomide and dexamethasone without elotuzumab.
Real-World RRMM Data Explore Dose Deescalation and Outpatient Use of Teclistamab
November 18th 2024During a Case-Based Roundtable® event, Hana Safah, MD, examined several real-world studies of dose frequency and outpatient administration of teclistamab in patients with multiple myeloma in the first article of a 2-part series.
Read More
